| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 1.3M | $2.25M | $1.73 | Feb 3, 2025 | Direct |
| Allogene Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Stock Option (Right to buy) | 615K | $1M | $9.62 | Jan 24, 2025 | Direct |
| PERRIGO Co plc | Director | Ordinary Shares | 20.3K | $612K | $30.22 | May 15, 2024 | Direct |
| Better Therapeutics, Inc. | Director | Common Stock | 1.03M | $175K | $0.17 | Dec 18, 2023 | Direct |
| Better Therapeutics, Inc. | Director | Common Stock | 53.3K | $9.06K | $0.17 | Dec 18, 2023 | By Parker Trust |
| Tricida, Inc. | COO, CFO and EVP | Common Stock | 262K | Dec 31, 2021 | By Geoffrey M. Parker and Jill Gofen Parker Rev. Trust dated 1/27/00 | ||
| Tricida, Inc. | COO, CFO and EVP | Employee Stock Option (right to buy) | 256K | Feb 28, 2022 | Direct | ||
| Tricida, Inc. | COO, CFO and EVP | Common Warrants | 167K | Nov 15, 2021 | By Geoffrey M. Parker and Jill Gofen Parker Rev. Trust dated 1/27/00 | ||
| Tricida, Inc. | COO, CFO and EVP | Common Stock | 63.6K | Dec 31, 2021 | Direct | ||
| Tricida, Inc. | COO, CFO and EVP | Common Stock | 55K | Dec 31, 2021 | By Equity Trust Company, Trustee of the Geoffrey M. Parker Rollover IRA | ||
| Tricida, Inc. | COO, CFO and EVP | Common Stock | 40K | Dec 31, 2021 | By Equity Trust Company, Trustee of the Geoffrey M. Parker Roth IRA | ||
| Better Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 15K | Jun 7, 2023 | Direct | ||
| ChemoCentryx, Inc. | Director | Common Stock | 0 | $50.95 | Oct 20, 2022 | By Delaware Charter Guarantee & Trust Company, Trustee FBO Mr. Geoffrey Monroe Parker IRA | |
| ChemoCentryx, Inc. | Director | Common Stock | 0 | $50.95 | Oct 20, 2022 | Direct | |
| ChemoCentryx, Inc. | Director | Common Stock | 0 | $50.95 | Oct 20, 2022 | Geoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust | |
| ChemoCentryx, Inc. | Director | Restricted Stock Unit | 0 | Oct 20, 2022 | Direct | ||
| ChemoCentryx, Inc. | Director | Stock Option | 0 | Oct 20, 2022 | Direct | ||
| PERRIGO Co plc | Director | Restricted Stock Units | 0 | May 15, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | Feb 3, 2025 | 1 | -$7.54K | 4 | Feb 5, 2025 | CHIEF FINANCIAL OFFICER |
| ALLO | Allogene Therapeutics, Inc. | Jan 24, 2025 | 2 | $0 | 4 | Jan 28, 2025 | CHIEF FINANCIAL OFFICER |
| ALLO | Allogene Therapeutics, Inc. | Oct 21, 2024 | 1 | -$103K | 4 | Oct 23, 2024 | CHIEF FINANCIAL OFFICER |
| ALLO | Allogene Therapeutics, Inc. | May 16, 2024 | 1 | $1M | 4 | May 20, 2024 | CHIEF FINANCIAL OFFICER |
| PRGO | PERRIGO Co plc | May 14, 2024 | 4 | $138K | 4 | May 16, 2024 | Director |
| ALLO | Allogene Therapeutics, Inc. | Jan 30, 2024 | 1 | $683 | 4 | Mar 6, 2024 | CHIEF FINANCIAL OFFICER |
| ALLO | Allogene Therapeutics, Inc. | Jan 25, 2024 | 2 | $0 | 4 | Jan 31, 2024 | CHIEF FINANCIAL OFFICER |
| BTTX | Better Therapeutics, Inc. | Dec 18, 2023 | 1 | $0 | 4 | Dec 20, 2023 | Director |
| ALLO | Allogene Therapeutics, Inc. | Oct 16, 2023 | 3 | $0 | 4 | Oct 17, 2023 | CHIEF FINANCIAL OFFICER |
| ALLO | Allogene Therapeutics, Inc. | Oct 16, 2023 | 0 | $0 | 3 | Oct 16, 2023 | CHIEF FINANCIAL OFFICER |
| BTTX | Better Therapeutics, Inc. | Jul 27, 2023 | 1 | $500K | 4 | Jul 31, 2023 | Director |
| PRGO | PERRIGO Co plc | Jun 13, 2023 | 1 | $331K | 4 | Jun 14, 2023 | Director |
| BTTX | Better Therapeutics, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
| PRGO | PERRIGO Co plc | May 17, 2023 | 3 | $133K | 4 | May 19, 2023 | Director |
| PRGO | PERRIGO Co plc | May 15, 2023 | 1 | $0 | 4 | May 17, 2023 | Director |
| BTTX | Better Therapeutics, Inc. | Apr 10, 2023 | 1 | $250K | 4 | Apr 12, 2023 | Director |
| PRGO | PERRIGO Co plc | Mar 6, 2023 | 1 | $190K | 4 | Mar 7, 2023 | Director |
| CCXI | ChemoCentryx, Inc. | Oct 20, 2022 | 9 | $0 | 4 | Oct 24, 2022 | Director |
| BTTX | Better Therapeutics, Inc. | Jun 13, 2022 | 1 | $36.2K | 4 | Jun 14, 2022 | Director |
| BTTX | Better Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
| CCXI | ChemoCentryx, Inc. | May 26, 2022 | 2 | $0 | 4 | May 31, 2022 | Director |
| CCXI | ChemoCentryx, Inc. | May 20, 2022 | 2 | $0 | 4 | May 24, 2022 | Director |
| PRGO | PERRIGO Co plc | May 17, 2022 | 4 | $132K | 4 | May 19, 2022 | Director |
| CCXI | ChemoCentryx, Inc. | May 2, 2022 | 2 | $180K | 4 | May 3, 2022 | Director |
| BTTX | Better Therapeutics, Inc. | Mar 29, 2022 | 1 | $32.2K | 4 | Mar 31, 2022 | Director |
| TCDA | Tricida, Inc. | Feb 28, 2022 | 1 | $0 | 4 | Mar 2, 2022 | COO, CFO and EVP |
| TCDA | Tricida, Inc. | Dec 31, 2021 | 1 | -$13.2K | 4 | Jan 4, 2022 | COO, CFO and EVP |
| PRGO | PERRIGO Co plc | Dec 16, 2021 | 1 | $184K | 4 | Dec 17, 2021 | Director |
| BTTX | Better Therapeutics, Inc. | Dec 14, 2021 | 1 | $98.8K | 4 | Dec 16, 2021 | Director |
| TCDA | Tricida, Inc. | Nov 15, 2021 | 2 | $1M | 4 | Nov 17, 2021 | COO, CFO and EVP |
| BTTX | Better Therapeutics, Inc. | Oct 28, 2021 | 2 | $0 | 4 | Nov 1, 2021 | Director |
| BTTX | Better Therapeutics, Inc. | Oct 28, 2021 | 0 | $0 | 3 | Nov 1, 2021 | Director |
| PRGO | PERRIGO Co plc | May 17, 2021 | 1 | $0 | 4 | May 19, 2021 | Director |
| PRGO | PERRIGO Co plc | May 7, 2021 | 3 | $130K | 4 | May 11, 2021 | Director |
| CCXI | ChemoCentryx, Inc. | Mar 10, 2021 | 5 | $0 | 4 | May 24, 2021 | Director |